通过对13种SARS-CoV-2变种的交叉反应性分析,合理预测免疫性聚类
Ziteng Liang1,2, Jincheng Tong2, Ziqi Sun2
1Graduate School of Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Journal of medical virology
|January 1, 2024
概括
为了应对突变的SARS-CoV-2变种,研究人员研究了跨菌株的免疫性. 使用双价免疫原或特定变异增强剂的联合策略实现了广泛的保护,XBB增强剂显示出更高的抗体水平.
科学领域:
- 病毒学和免疫学 病毒学和免疫学
- 疫苗开发 疫苗开发
- 传染病研究 传染病研究
背景情况:
- 像Omicron这样的SARS-CoV-2变种对疫苗诱导的免疫力构成威胁.
- 持续的突变需要广泛的免疫原来对抗不断演变的变种.
- 了解SARS-CoV-2变种之间的免疫性关系对于有效的疫苗设计至关重要.
研究的目的:
- 评估SARS-CoV-2变种之间的免疫性关系,从D614G到XBB.
- 评估针对SARS-CoV-2变种的不同免疫策略的有效性.
- 为了确定最佳的抗原选择,用于广泛的疫苗保护.
主要方法:
- 用各种SARS-CoV-2变种 (D614G到XBB) 接种几内亚猪疫苗.
- 测试了三种免疫策略:三剂单价,三剂双价,两剂D614G接着一个变体增强剂.
- 免疫性集群和中和抗体水平的分析.
主要成果:
- 鉴定出了三个不同的免疫原性集群:集群1 (D614G,Alpha,Beta,Gamma,Delta),集群2 (BA.1,BA.2,BA.2.75) 和集群3 (BA.2.75.2,BA.5,BF.7,BQ.1.1,XBB).这些集群包括:
- 用双价免疫原或D614G/XBB组合策略实现了广泛的保护.
- 与D614G和XBB等效剂量相比,XBB增强导致更高的中和抗体水平.
结论:
- 联合免疫策略,特别是使用双价免疫原或D614G与XBB,可以提供广泛的保护SARS-CoV-2变种.
- 疫苗抗原选择应优先考虑跨变体的抗原变化,以尽量减少频繁更新的需要.
- 这些发现支持开发防变体疫苗,重点关注关键的抗原变化.
相关概念视频
Cross-reactivity
31.1K
Overview
31.1K
Conjugated Proteins
18.3K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.3K


